These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Ultrastructural changes in the Golgi apparatus and secretory granules of HL-60 cells treated with the imino sugar N-butyldeoxynojirimycin. Neises GR; Woodman PG; Butters TD; Ornberg RL; Platt FM Biol Cell; 1997 May; 89(2):123-31. PubMed ID: 9351192 [TBL] [Abstract][Full Text] [Related]
6. Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. Wennekes T; van den Berg RJ; Donker W; van der Marel GA; Strijland A; Aerts JM; Overkleeft HS J Org Chem; 2007 Feb; 72(4):1088-97. PubMed ID: 17243712 [TBL] [Abstract][Full Text] [Related]
7. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Cox T; Lachmann R; Hollak C; Aerts J; van Weely S; Hrebícek M; Platt F; Butters T; Dwek R; Moyses C; Gow I; Elstein D; Zimran A Lancet; 2000 Apr; 355(9214):1481-5. PubMed ID: 10801168 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of glycogen breakdown by imino sugars in vitro and in vivo. Andersson U; Reinkensmeier G; Butters TD; Dwek RA; Platt FM Biochem Pharmacol; 2004 Feb; 67(4):697-705. PubMed ID: 14757169 [TBL] [Abstract][Full Text] [Related]
9. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Steet R; Chung S; Lee WS; Pine CW; Do H; Kornfeld S Biochem Pharmacol; 2007 May; 73(9):1376-83. PubMed ID: 17217920 [TBL] [Abstract][Full Text] [Related]
10. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. Platt FM; Reinkensmeier G; Dwek RA; Butters TD J Biol Chem; 1997 Aug; 272(31):19365-72. PubMed ID: 9235935 [TBL] [Abstract][Full Text] [Related]
13. Study on the Synthesis and Biological Activities of N-Alkylated Deoxynojirimycin Derivatives with a Terminal Tertiary Amine. Wang L; Fang Z Acta Chim Slov; 2020 Sep; 67(3):812-821. PubMed ID: 33533441 [TBL] [Abstract][Full Text] [Related]
14. Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases. Asano N; Nishida M; Kato A; Kizu H; Matsui K; Shimada Y; Itoh T; Baba M; Watson AA; Nash RJ; Lilley PM; Watkin DJ; Fleet GW J Med Chem; 1998 Jul; 41(14):2565-71. PubMed ID: 9651160 [TBL] [Abstract][Full Text] [Related]
15. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. Butters TD; Dwek RA; Platt FM Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898 [TBL] [Abstract][Full Text] [Related]
16. N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice. Kaidonis X; Byers S; Ranieri E; Sharp P; Fletcher J; Derrick-Roberts A Mol Genet Metab; 2016 Jun; 118(2):100-10. PubMed ID: 27106513 [TBL] [Abstract][Full Text] [Related]
17. Differential sensitivity of mouse strains to an N-alkylated imino sugar: glycosphingolipid metabolism and acrosome formation. van der Spoel AC; Mott R; Platt FM Pharmacogenomics; 2008 Jun; 9(6):717-31. PubMed ID: 18518850 [TBL] [Abstract][Full Text] [Related]
18. Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. Abe A; Arend LJ; Lee L; Lingwood C; Brady RO; Shayman JA Kidney Int; 2000 Feb; 57(2):446-54. PubMed ID: 10652021 [TBL] [Abstract][Full Text] [Related]